I am far from a short you old cogger. I am not a spry guy
I am far from a short you old cogger. I am not a spry guy myself. You can call me short if you feel that helps your argument with that 3rd rate cancer therapy. lol... I also have to say I feel that all drugs if they provide relief or help in any way have value. Maybe Trodelvy has value? Maybe it gets used after everything is exhausted? Maybe new information is released that gives it a better chance as a first use drug. I am happy for your investment and the rise you will see tomorrow when the news of Gilead buyout hits the stock price. GLTU.
My main point was market share and use and I believe Leronlimab should have the market share when it happens to get approved with that excellent safety record and mechanism of action that reduces CTC to zero and maintains that zero CTC. I hope and would like believe it will bridge the gap for a partial cure by stopping all future metastasis. Hopefully when used with other cancer treatments it might just be combined into a cure for all the solid tumor cancers. That remains to be seen but just think if we could be a part of curing some of the nastiest deadly cancers out there.
All I can say to you is that Leronlimab is going to be an Achilles heel for many Big Pharma companies if everything we know to be true actually holds to be true. I believe in our CEO Nader and have never said a cross word about Nader or the CYDY management team.
By the way, I have a 5 figure amount of stock and average $.34/share. Had my one year anniversary of ownership last month. I consider myself long and I have never sold a share of CYDY since my original purchase. Why you might ask. It’s because I believe in Leronlimab and it’s mechanism of action not just working for one indication but many anti inflammatory mechanisms of action and immune modulations and so likely working for many diseases. I am all in because I believe. Hoping for a great next 30 days! With two approvals and an uplisting and a cancer BTD filed. Not necessarily in any specific order. I will take all 4 in any order they come. Good luck to us all...
5
1
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Fermi's Roller Coaster: A Founder’s Stand Seems like Fermi Inc. is on a wild ride through the business landscape, and it's giving shareholders more whiplash than satisfaction these days. Toby Neugebauer, co-founder of Fermi and the loudest voice in the room, is feeling like his company is facing some serious turbulence and seems determined not to sit idly by as it hits...
Continue Reading
A Somber Day at NYSE: Reflecting on 9/11 September 11th grips the heart of NYSE every year, but this year's 25th-anniversary powerfully reverberates through its hallowed halls. The hustle of the trading floor halts for a moment at 9:20 AM ET, paying homage to those lost in the harrowing attacks. I've seen the markets flap in the wind of countless crises, but nothing's...
Continue Reading
Copper's New Pulse: PolarX Makes Waves in Alaska Ever hear about striking copper so rich it's practically shimmering? Well, PolarX Limited just might have hit that sweet spot up in the rugged expanses of Alaska. Let me tell you, when you're knee-deep in resources, like what they’re discovering at the Caribou Dome Project, it sure feels like you’ve struck modern-day...
Continue Reading
Toss out your one-size-fits-all real estate predictions; the Q2 2026 Buy-Side Index just unveiled some real whoppers about the housing market. What we're seeing isn't your typical year-over-year growth across the board. Nope, we're seeing splits as sharp as a knife between states. Some places are shooting up in price, while others seem to be stuck in mud. Price Surges and...
Continue Reading
They say you can never go home again, but don't tell that to Melissa Rivers. Rolling the dice on nostalgia and kicking off a new chapter, she's waltzing back to the Emmys red carpet for the first time in nearly 20 years. Alright, what's in it for investors? Not much—unless you're looking to invest in nostalgia. But there's something here about legacy, reinvention, and...
Continue Reading
Decoupling Oil Price and Production Response This oil market isn’t your usual rodeo. With Brent flirting with $100, it’s a seismic shift that’s not yielding new drills but redirecting capital to the existing infrastructure landscape. Ask yourself why we're not seeing the usual cavalry charge of new rigs. It’s simple: Pipeline mileage and producing wells have...
Continue Reading
Massive Prize Pools Emerge in Just Four Days I found myself eyeballing some jaw-dropping numbers from Americas Cardroom's latest poker series, the Online Super Series XL. It's not every day you see nearly a hundred tournaments rake in over $7.2 million in prize pools in just four days. From September 6th to 9th, a whopping 62,847 entries signed up to make an honest...
Continue Reading
Paving the Way for Seamless International Shipping Supply Maverick's got a new mantra, folks: simplicity. They're slicing through the mess of international shipping and bringing some much-needed clarity for customers in Canada, Australia, and New Zealand. It’s about time someone shook up the logistics playbook. The Nuts and Bolts of the New Shipping System Imagine being...
Continue Reading
They say good things come in bizarre packages, and that's exactly the case as David Boylan's Lick the Plate zany celebration marks 15 years on air with its 2,000th episode. If you think of radio as a predictable endeavor, well, you're not tuned into Lick the Plate. A Milepost Draped in Multicolored Fabrics When you're browsing through colorful avenues of radio fame, it's...
Continue Reading
Sustainability Investments: A Tale of Contrasts In the world of sustainability, a staggering $17 trillion has been poured into technologies over the past decade. That’s no chump change. But what do we have to show for it? According to Bain & Company’s latest report, this massive financial injection hasn’t exactly hit a home run. Progress, much like the stock market...
Continue Reading
Top 5 Most Recently Viewed Articles
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) stirred some chatter back when they granted inducement options to six newly hired employees. This was all part of their plan to snag top talent while keeping the growth engine humming in the cutthroat pharmaceutical sector. Inducement Options Breakdown: Strategy or Desperation? The board's compensation committee greenlit a...
Continue Reading
Powerball Jackpot Reaches a New Milestone As summer days turn into autumn, lottery enthusiasts across the country are feeling a surge of excitement with the Powerball jackpot climbing to an impressive estimated $1 billion. This substantial prize marks just the sixth instance in the game's history where the jackpot has surpassed the billion-dollar milestone, capturing...
Continue Reading
Update on Motion's Funding Success Motion, a top player in the realm of creative analytics and research, has recently captured attention with an important announcement. The company has successfully raised $30 million USD in Series B funding, which will significantly boost its services for creative strategists. This funding round was led by Inovia, with key contributions...
Continue Reading
Rubicon Organics Secures Key Certification for Export Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) is thrilled to announce a significant milestone in its journey as a premium cannabis producer. The company has been awarded the IMC-G.A.P. Equivalency Certification by Control Union, establishing itself as a serious player on the international cannabis stage....
Continue Reading
Leadership Changes at STERIS In a significant announcement, STERIS plc (NYSE: STE) shared that long-time Chief Financial Officer (CFO) Michael J. Tokich will be succeeded by Karen L. Burton, currently the Chief Accounting Officer. This transition comes after Tokich's impressive 17-year tenure as CFO, during which he played a pivotal role in the company's growth and...
Continue Reading